Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/10/16
End: 11/11/24
Due: 11/11/25
Phase: N/A
Priority: Normal
Start: 12/16/21
End: 05/26/23
Due: 05/26/24
Phase: N/A
Priority: Normal
Start: 09/13/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 01/24/23
End: 10/10/24
Due: 10/10/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Vincerx Pharma, Inc. | user2@example.com | None | 2016-02-10 | 2024-11-11 | 2025-11-11 | - | - | 2025-07-14 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | NCT04978779 | Vincerx Pharma, Inc. | user2@example.com | None | 2021-12-16 | 2023-05-26 | 2024-05-26 | - | - | 2025-07-14 |
| Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | NCT06034275 | Vincerx Pharma, Inc. | user2@example.com | None | 2023-09-13 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer | NCT05712889 | Vincerx Pharma, Inc. | user2@example.com | None | 2023-01-24 | 2024-10-10 | 2025-10-10 | - | - | 2025-07-14 |